← Eichor
Study identifier: NCT03977753 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Randomized, Placebo-controlled, Double Blind Study to Evaluate the Efficacy of 2LVERU®JUNIOR and 2LVERU® on the Treatment of Warts

Condition: Common Wart · Flat Wart · Plantar Wart  ·  Sponsor: Labo'Life

PhasePhase 4
Planned participants162
Who can joinAll sexes, 3 Years to no upper limit
Healthy volunteersNo

About this study

Human papillomavirus (HPV) infection is very common, as most people will experience infection during their lifetime. The most common manifestation of HPV infection is common warts. Common warts may appear at any age. Conventional treatments can be used to treat warts and they are based on two mechanisms: stimulation of cellular immunity against HPVs or destruction of the lesion. These treatments are based on the location of the wart and the degree of the symptoms. No specific antiviral therapy is available to cure warts and today, there is no treatment that allows the definitive eradication of the virus. The 2LVERU® has been available for more than 20 years, and has received a marketing authorization in Belgium by the Federal Agency for Medicines and Health Products (FAMHP). It is used as an immune regulator in the treatment of common warts (verruca vulgaris), flat warts (verruca plana) or plantar warts (verruca plantaris) caused by Human Papillomavirus. Since 2LVERU® has been made available, clinical observational data collected on treated patients have shown the beneficial effect on the disappearance of warts. The purpose of this placebo-controlled, randomized, double-blind trial is the comparison of the efficacy of the treatment on the disappearance of warts at the end of treatment (6-month visit) between the 2LVERU® JUNIOR and 2LVERU® versus the placebo group.

This description comes directly from the study's public registry record.

Talk to the study team

Charlotte Bolle  ·  (0)497 49 13 74  ·  charlotte.bolle@labolife.com

Laura FERTE  ·  (0)499 71 79 64  ·  laura.ferte@labolife.com

Always discuss trial participation with your own doctor first.

Locations (18)

Private PracticeArlon, BelgiumWithdrawn
Clinique Saint-Luc (Bouge)Bouge, BelgiumRecruiting
Private PracticeBrussels, BelgiumTerminated
Private PracticeÉcaussinnes-d'Enghien, BelgiumTerminated
Private PracticeFontaine l'Êveque, BelgiumSuspended
Private PracticeGhent, BelgiumRecruiting
Private PracticeGozée, BelgiumTerminated
Private PracticeHamme-Mille, BelgiumRecruiting
Private PracticeJuprelle, BelgiumWithdrawn
Private PracticeMons, BelgiumWithdrawn
Private PracticeNamur, BelgiumRecruiting
Private PracticeNamur, BelgiumWithdrawn

+ 6 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT03977753